Get the Stockscreener App
0.8899
9.18%
-0.09
After Hours:
.93
0.0401
+4.51%
iBio Inc stock is traded at $0.8899, with a volume of 497.80K.
It is down -9.18% in the last 24 hours and down -81.69% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$0.9799
Open:
$0.9768
24h Volume:
497.80K
Relative Volume:
0.84
Market Cap:
$11.88M
Revenue:
$2.05M
Net Income/Loss:
$-23.15M
P/E Ratio:
-0.1342
EPS:
-6.6319
Net Cash Flow:
$-16.93M
1W Performance:
-26.45%
1M Performance:
-81.69%
6M Performance:
-68.78%
1Y Performance:
-52.92%
1-Day Range:
$0.8713
$1.00
1-Week Range:
$0.8713
$1.245
52-Week Range:
$0.8713
$6.8908
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
0.8899 | 11.88M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
iBio Inc Stock (IBIO) Latest News
iBio stock touches 52-week low at $1.03 amid market challenges By Investing.com - Investing.com South Africa
iBio stock touches 52-week low at $1.03 amid market challenges - Investing.com Australia
iBio Highlights Advancements in Obesity Antibody Programs - TipRanks
iBio reports promising data on obesity treatment antibody By Investing.com - Investing.com South Africa
iBio reports promising data on obesity treatment antibody - Investing.com Australia
iBio stock touches 52-week low at $1.42 amid market challenges - Investing.com Australia
iBio stock touches 52-week low at $1.42 amid market challenges By Investing.com - Investing.com South Africa
Where Do Analysts Think The iBio Inc (NASDAQ: IBIO) Is Going - stocksregister.com
iBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays Bearish - MSN
Ibio reports preclinical results for antibodies in cardiometabolic and obesity pipeline - BioWorld MedTech
Ibio IncOn Track For Regulatory Submission For Ibio-600 In Q1 2026 - MarketScreener
iBio Reveals Promising Study Results for IBIO-600 - TipRanks
iBio announces data from non-human primate PK study of IBIO-600 - TipRanks
Game-Changing Clinical Data: iBio's New Drug Combines Muscle Growth with Massive Weight Loss - Stock Titan
iBio, Inc. Common Stock (IBIO): Among Stocks Insiders Were Buying In Q1 2025 - Insider Monkey
20 Stocks Insiders Were Buying In Q1 2025 - Insider Monkey
FY2025 Earnings Forecast for iBio Issued By Chardan Capital - Defense World
iBio (NYSEMKT:IBIO) Trading Down 2.9% – Time to Sell? - Defense World
iBio (NYSE:IBIO) Upgraded by StockNews.com to “Sell” Rating - Defense World
Contrasting iBio (NYSE:IBIO) & Pharmaxis (OTCMKTS:PXSLY) - Defense World
IBIO Stock Price and Chart — NASDAQ:IBIO - TradingView
iBio Inc. stock rises Monday, outperforms market - MarketWatch
$IBIO stock is up 12% today. Here's what we see in our data. - Nasdaq
iBio Inc. stock rises Friday, outperforms market - MarketWatch
iBio Inc. stock rises Thursday, outperforms market - MarketWatch
iBio stock soars to 52-week high, reaches $5.03 - Investing.com
iBio stock soars to 52-week high, reaches $5.03 By Investing.com - Investing.com South Africa
iBio Inc. stock falls Wednesday, underperforms market - MarketWatch
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
iBio Inc. stock falls Monday, still outperforms market - MarketWatch
iBio, Inc. Advances in Therapeutics and Leadership - TipRanks
iBio Inc. stock falls Friday, underperforms market - MarketWatch
iBio Inc. stock falls Thursday, underperforms market - MarketWatch
iBio to Begin Trading on the Nasdaq Stock Exchange - GlobeNewswire
iBio Inc. stock rises Wednesday, outperforms market - MarketWatch
iBio Announces Transfer to Nasdaq Capital Market - TipRanks
Can iBio's Nasdaq Move Transform Its Market Presence? Key Details Revealed - StockTitan
Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year? - Insider Monkey
10 Stocks Insiders Are Buying This Year - Insider Monkey
Ibio Inc Faces Financial Risk from Potential Stockholder Equity Dilution and Capital Raising Challenges - TipRanks
iBio Inc. stock falls Tuesday, underperforms market - MarketWatch
SEC Form 424B3 filed by iBio Inc. - Quantisnow
iBio Inc. stock falls Monday, underperforms market - MarketWatch
iBio Inc. (IBIO) reports earnings - Quartz
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):